Dec 10, 2021 / 03:00PM GMT
Operator
Ladies and gentlemen, welcome to Roche virtual event on analyst during ESMO IO. My name is Henrik, and I'm the technical operator for today's call. Kindly note that the webinar is being recorded. (Operator Instructions)
At this time, it's my pleasure to introduce you to Karl Mahler, Head of Investor Relations and Group Planning. Karl, the stage is yours.
Karl Mahler - Roche Holding AG - Head of IR
Yes. Thanks a lot, Henrik, for your kind introduction. Welcome to our ninth, actually, science call this year. So 9 events means that we really have lots of news flow -- positive news flow in the case of Roche, and this one is a particularly exciting one despite it's only in a Phase II (inaudible) only in a Phase II. And we have next week our last one in the course of ASH, where we basically testimony our broad and maybe best-in-class portfolio in hematology.
This is the program for today. We will have an updated -- and show to you an updated analysis from the Phase II CITYSCAPE study. Raymond Meng will do that. He is the Global Development Leader
Roche Holding AG Virtual Analyst Event During ESMO IO Transcript
Feb 14, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers